XBiotech Inc. XBIT
1.87 USD -0.08 (-4.10%)
At closeNov 5, 2026, 4:00 PM EST
1.87 0.00 0.00%
After hours · Nov 5, 4:00 PM ET
1.85 Day range 2.01
1.85 52-week range 2.94
- YTD
- -21.76%
- 1 year
- -11.79%
News
benzinga.com XBiotech Appoints Jan-Paul Simard Co-CEO, Effective Oct. 23 XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23,…
globenewswire.com XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside…
benzinga.com XBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Arm Were Alive, Surpassing Threshold Of 42, More Surviving Patients XBiotech Inc. (NASDAQ: XBIT) today announced positive final efficacy results from the randomized Phase II portion of the multicenter TASKIN clinical trial. The investigator-sponsored study—funded by…
globenewswire.com XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival.
defenseworld.net XBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average – What’s Next? XBiotech Inc. (NASDAQ: XBIT - Get Free Report)'s stock price passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $2.27 and traded as low as…- benzinga.com XBiotech Says IND Application For V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path For U.S. Patient Enrollment XBiotech Inc. (NASDAQ:XBIT) today announced that its Investigational New Drug (IND) application for V-SPINE (PT064), a Phase II, double-blind, placebo-controlled, randomized study evaluating the…
globenewswire.com XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
benzinga.com XBiotech Q1 EPS $(0.18) Up From $(0.36) YoY XBiotech (NASDAQ:XBIT) reported quarterly losses of $(0.18) per share. This is a 50 percent increase over losses of $(0.36) per share from the same period last year.
defenseworld.net Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB) IN8bio (NASDAQ: INAB - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses…
defenseworld.net Head-To-Head Comparison: XBiotech (NASDAQ:XBIT) and Psyence Biomedical (NASDAQ:PBM) Psyence Biomedical (NASDAQ: PBM - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies…
benzinga.com XBiotech Announces John Simard To Retire As CEO, To Continue As Chairman; Sushma Shivaswamy Appointed Interim CEO Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. XBiotech, Inc. ("XBiotech" or the "Company")…
defenseworld.net XBiotech (NASDAQ:XBIT) Share Price Crosses Above Fifty Day Moving Average – Should You Sell? XBiotech Inc. (NASDAQ: XBIT - Get Free Report) passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $2.47 and traded as high as $2.68. XBiotech…- benzinga.com XBiotech Q3 EPS $(0.20) Down From $(0.16) YoY XBiotech (NASDAQ:XBIT) reported quarterly losses of $(0.20) per share. This is a 25 percent decrease over losses of $(0.16) per share from the same period last year.
benzinga.com XBiotech Q2 EPS $(0.06) Up From $(0.43) YoY XBiotech (NASDAQ:XBIT) reported quarterly losses of $(0.06) per share. This is a 86.05 percent increase over losses of $(0.43) per share from the same period last year.
accessnewswire.com The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech…
accessnewswire.com An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech…
accessnewswire.com The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
accessnewswire.com An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
accessnewswire.com The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
accessnewswire.com An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
accessnewswire.com The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
accessnewswire.com An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
accessnewswire.com The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
accessnewswire.com An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
accessnewswire.com The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
accessnewswire.com XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
accessnewswire.com The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…- benzinga.com What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? XBiotech reveals results from its Phase 1/Phase 2 1-BETTER Study for advanced pancreatic cancer, highlighting the safety and tolerability of Natrunix with the ONIVYDE + 5-Fluorouracil + Leucovorin…
- benzinga.com XBiotech Shares Results From Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment For Advanced Pancreatic Cancer XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com XBiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke XBiotech Inc. (NASDAQ:XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com XBiotech Announces Enrollment Completion Of Phase II, Placebo Controlled, Multicenter Study For Natrunix In Pancreatic Cancer XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in…
- benzinga.com XBiotech Announces First Patient Begins Novel Natrunix Therapy In Phase II Rheumatoid Arthritis Clinical Trial XBiotech Inc. (NASDAQ:XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis.…
- benzinga.com Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers
- benzinga.com Dow Jumps Over 100 Points; US Housing Starts Rise In April U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.37% to 33,135.37 while the NASDAQ…
- benzinga.com XBiotech Announces First Subject Enrollment In Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke XBiotech Inc. (NASDAQ:XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Hutrukin…
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 79 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday saw 177 companies set new 52-week lows.
benzinga.com XBiotech Announces First Patient Enrolled Into The French National Cancer Institute Sponsored Phase I/II/III Clinical Study For Natrunix Therapy For Colorectal Cancer XBiotech (NASDAQ:XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of…
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 1076 companies hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 507 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 429 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 238 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 273 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 195 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 109 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 92 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 550 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the Thursday's session, 100 stocks hit new 52-week lows.